<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 172 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page171.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=172">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 172 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 172</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=172"><img src="../thumb/172.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Blood and Haemopoeitic - 8.2                                                   2020-04 / 139

                   THE NOAC* YOU AND YOUR PATIENTS CAN RELY ON


                     *NOAC = non-vitamin K oral anticoagulant

       as therapeutically equiv., imp. liv./kidn.funct., elderly, allerg.react.  com.strong P-glycoprot.inhibit.(ie.amiodarone/ quinidine &   zole, peak & total expos.decr.by rifampicin/hypericum perforatum/
       hist.exp to hepar./low molecul.weight hepar., reg.monit.of platelet   verapamil): 150 mg once dly.  carbamazepine (P-gp.induc), plasma conc. incr.with concom.P-gp.
       count throughout treatm., consid.poss. thrombocytopen.in the event   Ven.thromboembol.(VTE) prev.follow.knee replacem.surg:   inhibits.e.g. amiodarone/ verapamil/quinidine/ketoconazole/ ticagre-
                      3
       of thrombocytopen. &lt;100 000/mm /signific.decr.in platelet count/   Init.within 1-4 hrs.of complet. surg.with 110 mg, thereaft.contin.  lor/ clarithromycin, concom.acetylsalic. acid/ NSAIDs & clopidogrel
       worsen.of init.thrombos.while on ther./thrombos. while on treatm./  with 2 caps once dly.x10 days. If not init.on day of surg.init. treatm.  poss.incr.maj.bleed. risk., risk of bleed.pos incr.with unfract.heparins
       dissemin.intra-vascul.coagulat., substitut.with Fraxiparine should not   with 2 caps.once dly. Mod.ren.impairm: Use 75 mg caps instead   (except at dos.necess.to maint.patency of a centr. ven./arter.cath.)&
       be consid. where thrombocytopen.has occurr.with another hepar./low   of 110 mg caps.  heparin derivativ./low molecul. weight heparins/fondaparinux/ de-
       molecul.weight hepar., concom.oral anticoags/agents which affect   Ven.thromboembol.(VTE) prev.follow.hip replacem. surg:   sirudin/ thrombolyt.agents/GPIIb/IIIa recept. antagon./ ticlopidine/
       platelet funct., concom.IV nitroglycerine.  Init.within 1-4 hrs.of complet. surg.with 110 mg, thereaft.contin.  dextran/sulfinpyrazone/ rivaroxaban/ prasugrel/Vit.K antagon & the
       Drug interactions: Anticoag.act.poss counteract. by digital./tetra-  with 2 caps once dly.x28 days. If not init.on day of surg.init. treatm.  P-gp inhibits. itraconazole/tacrolimus/ciclosporin/ ritonavir/ tipra-
       cycl./nicotine & antihistamines.  with 2 caps.once dly. Mod.ren.impairm: Use 75 mg caps instead   navir/nelfinavir & saquinavir., concom. SSRIs/SNRIs may incr bleed.
       HEPARIN SODIUM FRESENIUS AMPS & VIALS,    of 110 mg caps.  risk., incr. expos.with dronedarone
                                     Reduc.stroke & system.embol.risk in pts. with atrial fibrillat:
       Fresenius Kabi [P/S]                                       See also MDR page 274.
       Heparin sodium.               Recomm.dly.dos: 300 mg as 150 mg 2xdly. Cont.ther.life-long. Mod.  XARELTO, Bayer
       Indications: Arterial & ven.thrombos., thromboembol. prophylax.  ren. impairm: No dos.adjustm.necess. Pts.80 yrs.or above & those   Rivaroxaban
       (S4) INJ J/8.2/405, 406       with potent.risk of maj.bleed: Dly.dos.220 mg as 110 mg 2xdly.  Indications: Ven.thromboembol.prev.in pts undergo. maj.low.limb.
       730599-019: 1 000 IU/ml, 10x1 ml amps, R187,37  Treatm.of ac.DVT &/ pulm.embol: Recomm. dly. dos.: 300   orthopaed.surg.
       782254-004: 1 000 IU/ml, 10x5 ml vials, R216,14  mg as 150 mg 2xdly. follow. treatm. with a parenter.anticoag.for at   (S4) TABS 10. 42/8.2/1046
       730602-001: 5 000 IU/ml, 10x1 ml amps, R361,46  least 5 days. Contin.ther for up to 6 mnths. Mod.ren. impairm: No   714238-001: 10 mg, 10, R340,03
       782262-007: 5 000 IU/ml, 10x5 ml vials, R581,59  dos.adjustm.necess. Pts.with potent.risk of maj.bleed: Benef.to   714238-002: 10 mg, 30, R1 020,22
       Dosage: Adults: Usual.init.IV dos: 12 500 units IVI follow.by 10 000   outweigh bleed.risk  Dosage: 1 tab once dly. Take init.dos.within 6-10 hrs.aft surg.prov.
       units 4 hrly.to keep the clott.time, test.not less than 3 hrs.aft.last inj.  Prevent. of recurr.DVT &/ pulm.embol.: Recomm.dly.dos: 300   haemostas.est. Treatm.durat.depends on type of surg. Aft.maj.hip
       at about 3xpre-treatm.fig. The dos.range for this purpose is 6 000-  mg as 150 mg 2 x dly.  Cont.ther.life-long.depend.on pt. risk facts.   surg. x5 wks. & aft.maj.knee surg.x2 wks.
       12 000 units. For contin.infus.add 10 000-20 000 units to 1 litre NaCl   Mod.ren.impairm: No dos.adjustm.necess. Pts.with potent.risk   (S4) TABS 15, 20, 46/8.2/0111, 0112
       or dextr.inj.start.at 20 drps./ min.  of maj.bleed: Benef.to outweigh bleed.risk  Indications: Stroke & syst.embol.prevent.in pts.with non-valvul.
       Childr: Init.50 units/kg bm by IV infus.in dextr.5% then incr.to 100   Contraindications: Sev.ren.impairm., haemorrhag. manifestat.,   atrial fibrillat.(SPAF), deep vein thrombos.& pulm.embol.treatm.,
       units/kg 4 hrlyto keep clott.time at 20-30 mins  bleed.diathes., spontan./ pharmacologic.haemostas.impairm., mod.  recurr.DVT & PE prevent.
       If bld.transfus.are reqd.dur.anticoag.ther.3 units/ml may be added to   to sev.hepat.impairm., organ les.at risk of clinic.signific.bleed.incl.
       transfus.bld.in addit.to dos. already being admin. Bleed.from operat.  haemorrh.stroke within last 6 mnths., indwell.spin./epidur.catheter   719859-001: 15 mg, 42, R1 428,36
                                                                  719860-001: 20 mg, 28, R952,26
                                        st
       site unlikely if start.aft.4  post-op day.  & dur.1  hr.aft.remov., concom.ketoconazole, prolong.co-admin.with
                 th
       Venous thromboembol: IV load.dos.of 5 000 units. (10 000 units   warfar./ heparins, unfractionat.heparin.(but may be admin. at dos.   Dosage: Admin.with food. No dos.adjustm.reqd. based on body
       poss.reqd.in sev.pulm. embol.) follow.by contin.IV infus.of 1 000-  necess.to maint.patent centr.ven/arter. catheter)/heparin derivat./  weight.
       2 000 units/ hr.or 15 000 units SC inj.12 hrly. Alternat. intermitt.IV   low molecul.weight heparin/fondaparinux/desirudin/thrombolyt.   SPAF: Recomm.dos: 20 mg once dly. 15 mg once dly in mod.ren
       5 000-10 000 units 4-6 hrly. undil./dil.in 50-100 ml Dextr5%/NaCl   agents/GPIIb/IIIa recept.antagon./clopidogrel/ ticlopidine/ticagre-  impairm.(creat.clear.&lt; 50-30 ml/min). Cont.for as long as stroke &
       0,9%. Childr. & small adults are given low.IV dos.follow.by maint.   lor/dextran/sulfinpyrazone & vit.K antagon., suspect.infect.endo-  syst. embol.risk fact.persist. Miss.dos: Admin.immed. & contin.with
       with contin.infus.of 15-25 units/kg/hr or 250 units/kg SC 12 hrly.  cardit., prosthet.heart valve replacem., safety in pregn.& lactat.not   1x dly.intake as recomm.on foll. day. Dos.not to be doubl.to make up
       Postop ven.thromboembol.prophylax: 5 000 units SC 2 hrs.  est., not recomm.in childr.  for miss.dos. on same day. Max. dly dos: 20 mg. Convers. from
       bef.surg.then 8-12 hrly.x7 days or till pt.ambulant. Simil.dos.used to   Side effects: Bleed.(of var.degrees)/signs of bleed., anaem., throm-  warfar: Stop warfar.init. ther.when INR ≤ 3,0. Convers.to war-
       prev. thromboembol.dur.pregn.in women with DVT or pulm. embol.  bocytopen., hypersens. reacts., intracran.haemorrh., haematoma,   far: Ensure contin.adeq. anticoag.dur.transf.to alt.anticoag. Admin.
                                                                                           st
       hist. Dos.may need to be incr.to 10 000 units.12 hrly dur.3  trimmest.  epistax., haemoptys., GI disords.incl.haemorrh.& ulc., dysphag.,   warfar. concurr.until INR ≥ 2,0. Admin.std. warfar. dos.for 1  2 days
                              rd
       Contraindications: Hepar.induc.thrombocytopen., haemorrh.bld.  abnorm.hepat.funct., skin/ urogenit. haemorrh., haemarthros., inj/  of convers.period foll.by warfar. dos.guid.by INR test. While on both
       disords.esp.thrombocytopen.& haemophil. act./suspect.haemorrh.  cathet./ incis.site haemorrh., traumat.haematoma, post proced.haem-  Xarelto & warfar.INR not to be test.earl.than 24 hrs aft. prev.dos.but
       esp. cerebrovasc. or GI except.in dissemin.intravasc. coagulat., cer-  orrh.& discharge aft.hip and knee replacem.ther., post.op.anaem.  prior to next Xarelto dos. Once Xarelto discont.INR test.may be done
       ebr./aortic aneurysm, sev.or uncontrol. hypertens., threat.abort., rec.  Warnings and special precautions: No tests to monit.coagulat.  24  hrs.aft.last dos. Convers.from parenter. anticoags: Start ther.
       childbirth, subac.bact.endocardit., pericardit., sev.vasculit., act. cavi-  currently avail.although aPTT tests may help determine excess an-  0-2 hrs.bef.next sched. admin.of parenter.meds./at time of discont.
       tat.TB, visc.carcinoma if intracran. metastas. poss., pept.ulcerat.,   ticoag.activ. in pts.who are bleed., search for bleed.site in case of   of contin.admin.parenter. meds.e.g.IV heparin. Convers.to parenter.
       dur./aft.eye/brain or spin.cord surg.or trauma, prior to lumb.punct.or   unexplain.fall in haemoglob./ haematocrit/ BP, risk of epidur./spin.  anticoags: Discont. Xarelto & give 1  dos.of parenter. anticoag. at
                                                                                  st
       region.anaesthet.block, surgic./traumat.wounds result.in large open   haematoma incr. in cases of traumat./rep.punct. & prolong. eipdur.   time next Xarelto dos.would have been taken.
       surf., sev.ren./hepat.impairm., oesophag.varices.  cathet.use, 1 hr.interv.aft.cathet. remov. bef.admin.1  dos.& freq.  DVT & PE treatm: Init.15 mg 2x dly for 1  3 wks. foll.by 20 mg once
                                                                                   st
                                                           st
       Side effects: Allerg./anaphylact.reacts., trans. alopec., osteoporos.,   neurologic.S&S observat. reqd., incr.bleed risk.in pts.with antiphos-  dly.for contin. treatm.& prev. of recur.DVT & PE. Cont.ther.as long
       spontan.fract., haemorrh., thrombocytopaen.  pholip. syndr., concom.antiplatel./strong P-glycoprot. inhibit incr.risk   as VTE risk persists. Miss.dos: Admin.Xarelto 15 immed.to ensure
       Special precautions: Sev.hypertens., rec.cerebr. thrombos., el-  of maj.bleed.partic.in pts. ≥ 75 yrs, concom.P-glycoprot induc., incr.   30 mg/day intake if dos.miss.dur. 2x/day treatm. phase. 2 x15  mg
       derly women.                  bleed. risk in mod.ren.impairm., discont.in ac.ren. fail., short-term   may be taken at once then cont.with 15 mg 2x/day as recomm.on
       Interactions: Caut.with concom.oral anticoags./ meds. affect.  NSAID peri-op analges.not assoc. with incr.bleed.risk, assess ren.   foll. day. If dos.miss.dur.Xarelto 20 treatm.phase admin.Xarelto 20
       platelet.funct.(eg aspir./ dipyrimidamole), poss.incr.haemorrh.risk.  funct. when it’s suspect.ren.funct.may deterior.& in elderly bef.  immed. To ensure 20 mg/day intake then cont.with reg.20 mg once
       with NSAID’s, meds.affect.coagulat.process.incr. haemorrh. risk incl.  init.ther., assess ren.funct.at least 1x/yr., avoid.init.verapamil ther./  dly as recomm. on follow.day. Recomm.max.dly.dos: 30 mg dur. 1   st
       dextrans/streptokin./high dos.penicill./some cephalospor.& contrast   simultan.ther.in hip & knee replacem.pts., wait 24 hrs.in hip & knee   3 wks.of treatm.& 20 mg in follow. treatm.phase. Convers.from
       med./asparagin.& epoprosternol, oral anticoag.control estim.poss.  replacement surg & 12 hrs.in stroke & system embol.risk reduct.&   warfar: Stop warfar. & init Xarelto 15 ther.once INR is ≤ 2,5. Con-
       modif.by act.on prothromb., incompatibil.report.with alteplase/   treatm./prevent.of DVT &/pulm.embol.aft.last dos.bef.switch.to   vers.to warfar: Ensure cont.adeq. anticoagulat. dur.any transit.to
       amikac.sulph./amiodarone HCl/ampicill. sod./ protinin/benzylpeni-  parenter.anticoag., when switch.from parenter. anticoags. do not   alt.anticoag. Warfar.to be giv.concurr.until.INR ≥ 2,0. For 1  2 days
                                                                                           st
       cill./cefalot.sod./ciprofloxac./cytarabine/dacarbazine/daunorubic.  init.ther.0-2 hrs.bef.the next. sched. parenter.dos., discont.Vit.K an-  of convers. per.std.warfar.dos.to be used follow.by warfar.dos.guid.
       HCl/diazep./dobutam.HCl/doxorubic.HCl/droperidol/erythromyc.  tagon. ther. when switch.to Pradaxa ther.for stroke & system. embol.   by INR test while on both Xarelto & warfar. INR not to be test.earlier
       lactobion./gentamic.sulph./haloperid./hyaluronidase/hydrocortis.Na   risk reduct./treatm.or prevent.of DVT &/ pulm. embol.as soon as INR   than 24 hrs aft.prev.dos.but prior to next Xarelto dos. Once Xarelto
       succin./kanamyc.sulph./meticill.sod./ netilmicin.sulph./some opiod   &lt;2,0, pt.to remain on Pradaxa in stroke & system.embol.risk reduct.   discont.INR test.may be done reliabl.24  hrs.aft. last dos. Convers.
       analges./ oxytetracyc./ some phenothiaz./polymyxin B sulph./ strep-  ther. where cardiovers.necess., in hip & knee replacem. surg.pts.do   from parenter. anticoag: Start Xarelto 0-2  hrs.bef. next sched.
       tomyc.sulph./tetracycl./tobramyc. sulph./ vancomyc.HCl/ vinblastine   not take double dos.for miss. indiv.dos., in stroke & system.embol./   admin.of parenter.meds.or at the time of discont.continuous.admin.
       sulph./ cisatracur. besilat./labetal.HCl./levofloxac./ nicardip. HCl/re-  treatm. or prevent.of DVT &/pulm.embol.pts.a miss. indiv.dos.may be   parenter.meds. e.g.IV heparin. Convers.to parenter.anticoags:
       teplase and vinorelb.tartrate, inactiv. by cefmetazole.  taken upto 6 hrs.prior to next sched.dos., condits.with incr.bleed.risk,   Discont. Xarelto & giv.1  dos.of parenter. anticoag. at the time that
                                                                            st
       PRADAXA, Ing.Pharm &          maj trauma/ bact.endocardit/rec.biopsy incr. haemorrhag. risk, pts.  the next Xarelto dos. would have been taken.
       Dabigatran etexilate          underg. surg./invas.proced. at incr.risk for bleed., discont.ther.24 hrs.  Contraindications: Clinic.signific.act.bleed.(eg intracran./GI
       Indications: Ven.thromboembol.prev.in pts undergo. hip & knee   prior to invas./ surg.proced.& 2-4 days bef.maj.surg./pts. at high.risk of   bleed.), signif.hepat.dis.with/ without assoc.coagulopathy lead.to
       replacem.surg., reduc.stroke & system.embol.risk in pts.with atri-  bleed., discont.5 days bef.surg.if sev. ren.dysfunct.occ., if ac.intervent.  clinic. bleed. risk, pregn.& lactat., heredit.lact./galact.intol., no clinic.
       al fibrillat., treatm.of ac.& prevent.of recurr. DVT &/ pulm. embol.  req.delay. surg. if poss.untill &gt;12 hrs.aft last dos., treatm.to be resum.  data avail.for childr.upto 18 yrs., known exist. inherit.bleed.disords.,
       (S4) CAPS, 42/8.2/0130, 0131, 45/8.2/0162  post-proced.aft.complete haemostas., use of fibrinolyt.agents for   safety & effic.not studied in pts.with prosthet.heart valv., no data
       714548-001: 75 mg, 30, R546,42  treatm.of ac.ischaem. stroke may be consid.if pt.pres.with TT/ECT/  avail. to support.that Xarelto 20 (Xarelto 15 in pts. with mod.or sev.
       714548-002: 75 mg, 60, R1 092,84  aPTT not exceed.up.lim.of norm.accord.to loc.ref. range., appropr.  ren. impairm) prov.adeq. anti-coagul.in pts.with prosthet.heart valv.
       714547-001: 110 mg, 30, R546,42  meas.such as test.for occult bld. in stool/test.for drop in haemoglob.  Side effects: Occult/overt bleed.result.in post haemorrhag.anaem.,
       714547-002: 110 mg, 60, R1 092,84  suggest.if bleed. clin.suspect., start warfarin 3 days bef. discont. when   thrombocythem., tachycard., GI disturbs., loc./periph.oed., unwell
       712919-001: 150 mg, 60, R1 092,84  switch.from PRADAXA to warfar.in pts. with CrCl ≥ 50 mL/min, start   feel., fev., abnorm. hepat.funct., allerg.react./dermatit., wound secret.,
       Dosage: Delay treatm.if haemostas.not secur.  warfar.2 days bef. discont.when switch.from PRADAXA to warfar. in   extremit.pain, CNS effs., ren. impairm., prurit., skin rash, urticar., con-
       Adults:                       pts.with CrCl ≥ 30 - &lt; 50 mL/min, concom. dronedarone not recomm.  tus., hypotens., Xarelto 15 & 20 also: eye haemorrh. incl.conjunctiv.,
       Ven.thromboembol.(VTE) prev.follow.hip & knee replacem.  Interactions: Incr.bleed.risk with treatm.act.on haemostas/ coagu-  gingiv.bleed., GI tract/rect./post-proced./ musc./cerebr.& intracran./
       surg: 220 mg once dly. Mod. ren.impairm: 150 mg once dly. Con-  lat.incl.Vit K antagon., AUC & C max incr.with quinidine & ketocona-  urogenit. tract/ cutan.& subcut.haemorrh., dry mouth, fatig., asthen.,
                            S4 Pradaxa ® . 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131. S4 Pradaxa ® . 150 mg. Each capsule contains 150 mg of dabigatran
                            etexilate base (as mesilate salt). Reg. No. 45/8.2/0162. For full prescribing information refer to the professional information approved by the Regulatory Authority.
                            Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100406. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page171.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>&nbsp;&nbsp;&nbsp;<a href="page175.html">175</a>&nbsp;&nbsp;&nbsp;<a href="page176.html">176</a>&nbsp;&nbsp;&nbsp;<a href="page177.html">177</a>
             </td>
             <td width="35%"><a href="page173.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page173.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
